Advanced search
Publication Cover
Gynecological Endocrinology Volume 38, 2022 - Issue 4
Submit an article Journal homepage
2,079
Views
2
CrossRef citations to date
0
Altmetric
CONTRACEPTION OR MENOPAUSE STILL HAVE

Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg

Pedro-Antonio Regidora Exeltis Europe, Ismaning, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9551-2847
ORCID Icon,
Santiago Palaciosb Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
&
Enrico Collic Exeltis HealthCare Madrid, Madrid, Spain
Pages 333-338 | Received 18 Nov 2021, Accepted 22 Feb 2022, Published online: 09 Mar 2022

References

  • Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2008;61:171–180.
  • Schindler AE. Non-Contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013;11:41–47.
  • Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32(9):749–751.
  • PRAC referral assessment report. Procedure under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data. Combined hormonal contraceptives containing medicinal products INN: chlormadinone, desogestrel, dienogest, drospirenone, etonogestrel, gestodene, nomegestrol, norelgestromin or norgestimate. 2013. Procedure No. EMEA/H/A-31/1356.
  • WHO Medical eligibility criteria for contraceptive use. 5th ed. 2015; 47–61.
  • Jabbour HN, Kelly RW, Fraser HM, et al. Endocrine regulation of menstruation. Endocr Rev. 2006;27:17–46.
  • Smith OP, Critchley HO. Progestogen-only contraception and endometrial breakthrough bleeding. Angiogenesis. 2005;8:117–126.
  • Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75mg and levonorgestrel 30mg daily. Hum Reprod. 1999;14:982–985.
  • Rice C, Killick S, Hickling D, et al. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod. 1996;11(4):737–740.
  • Palacios S, Regidor PA, Colli E, et al. Oestrogen-free oral contraception with a 4 milligram drospirenone-only pill: new data and a review of the literature. Eur J Contracept Reprod Health Care. 2020;25(3):221–227.
  • Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92:439–444.
  • Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98:1549–1557.
  • Vogel B, Acevedo M, Appelman Y, et al. The lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet Commiss. 2021;397(10292):2385–2438.
  • Bateman BT, Shaw KM, Kuklina EV, et al. Hypertension in women of reproductive age in the United States: NHANES 1999–2008. PLoS One. 2012;7:e36171.
  • Wilsgaard T, Schirmer H, Arnesen E. Impact of body weight on blood pressure with a focus on sex differences: the Tromso study, 1986–1995. Arch Intern Med. 2000;160:2847–2853.
  • Wilson PWF, D’Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867–1872.
  • Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016;118:1723–1735.
  • Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet. 2011;378:1297–1305.
  • Collaborators GBDT. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the global burden of disease study 2015. Lancet. 2017;389:1885–1906.
  • Practice Guideline. ACOG practice bulletin no. 206: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019;133:e128–e150.
  • Farley TM, Meirik O, Chang CL, et al. Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 1998;52:775–785.
  • Curtis KM, Mohllajee AP, Martins SL, et al. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception. 2006;73:179–188.
  • Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med. 1988;319:1313–1317.
  • Kuhl H. Effects of progestogens on haemostasis. Maturitas. 1996;24:1–19.
  • Winkler UH. Hormone replacement therapy and haemostasis: principles of a complex interaction. Maturitas. 1996;24:131–145.
  • Schindler AE. Differential effects on progestins on haemostasis. Maturitas. 2003;46:31–373.
  • Regidor PA, Colli E, Palacios S. Overall and bleeding-related discontinuation rates of a new oral contraceptive containing 4 mg drospirenone only in a 24/4 regimen and comparison to 0.075 mg desogestrel. Gynecol Endocrinol. 2021;37(12):1121–1127.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.